Delving into the Latest Updates on RSVpreF with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

recombinant respiratory syncytial virus pre-fusion F protein, water for injections(Pfizer), Respiratory Syncytial Virus Subtype A Stabilized Prefusion F protein/Respiratory Syncytial Virus Subtype B Stabilized Prefusion F protein, Respiratory Syncytial Virus Vaccine

+ [6]

Target

RSV F protein

Action

modulators

Mechanism

Respiratory syncytial virus F protein modulators(Respiratory syncytial virus F protein modulators)

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Pneumonia due to respiratory syncytial virusRespiratory Syncytial Virus InfectionsLower Respiratory Tract Infections

Inactive Indication-

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Australia Pty Ltd.Pfizer Europe MA EEIG

Pfizer Inc.

+ [2]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Canada (04 Jan 2023),

Lower Respiratory Tract Infections

RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States)

Login to view timeline

Respiratory syncytial virus (RSV) is the leading cause of hospitalization in young infants in Canada. While most babies recover, RSV can cause severe breathing problems and place major stress on families and the health system. Infants born to pregnant women and people with HIV, even if they do not acquire the virus, face higher risks of RSV illness. This is partly because HIV increases the chance of preterm birth and can reduce the amount of protective antibodies passed to the baby during pregnancy.
Two new tools now exist to prevent RSV. One is a vaccine given in late pregnancy (RSVpreF), which boosts antibodies that cross the placenta and protect the baby at birth. The other is a long-lasting antibody (nirsevimab) given directly to infants after delivery. Both work well in the general population, but pregnant people living with HIV were excluded from the original studies. Health care providers therefore do not know if perinatal vaccination provides enough protection for these babies.
This study will follow 20 pregnant women/people with HIV at BC Women's Hospital who receive the RSVpreF vaccine. Antibody levels will be measured before and after vaccination from the pregnant recipient, and in infant blood sample, to see how well protection is transferred to infants. We will also assess vaccine safety, birth outcomes, and parental views on RSV immunization. Findings will guide Canadian policies to ensure that all infants, including those exposed to HIV, have equitable access to RSV protection.

Start Date01 Sep 2026

Sponsor / Collaborator

University of British Columbia

NCT07235397

/ Not yet recruitingNot Applicable

Evaluating the Benefits Of RSV MaternaL vAccination Using a Scottish National Dataset.

This study will use a retrospective cohort design and will be conducted within routinely collected national healthcare and statutory demographic datasets held by PHS and National Records of Scotland (NRS). As such, there will be no active enrollment of study participants, no direct contact with study participants, no collection of any primary data outside of the standard of care (SOC), and no requirement for informed consent.
This study design was chosen due to several advantages, over other possible designs, including the ability to evaluate incidence of study outcomes in exposed and unexposed infants, ability to follow infants longitudinally to evaluate study outcomes through 12 months of age, and ability to evaluate all-cause outcomes.
Study endpoints, including RSV-associated LRTD hospitalization and RSV-associated hospitalization, among infants born to ABRYSVO-vaccinated mothers (exposed group) will be compared with those among infants born to ABRYSVO-unvaccinated mothers (comparison group) initially from birth through 6 months of age, with later analysis from birth through 12 months as the infants reach this age threshold and their data become available.

Start Date30 Jul 2026

Sponsor / Collaborator

Pfizer Inc.

NCT07653100

/ RecruitingPhase 3

A PHASE 3 STUDY IN INDIA TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS

The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.

Start Date22 Jun 2026

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with RSVpreF

Login to view more data

100 Translational Medicine associated with RSVpreF

Login to view more data

100 Patents (Medical) associated with RSVpreF

Login to view more data

573

Literatures (Medical) associated with RSVpreF

31 Dec 2026·Human Vaccines & Immunotherapeutics

Parental acceptability of new RSV preventive therapies for infants: A cross-sectional survey in Canada

Article

Author: Moss, Stephana Julia ; Lee, Janet S W ; Vadlamudi, Nirma Khatri ; Castillo, Eliana ; MacDonald, Shannon E ; Dubé, Ève ; Bolotin, Shelly ; Halperin, Scott A ; Fitzpatrick, Tiffany ; Greyson, Devon ; MacDonald, Jade ; Manca, Terra ; Buchan, Sarah A ; Comeau, Jeannette L ; Papenburg, Jesse ; Parsons Leigh, Jeanna ; Blanchard, Wade ; Halperin, Donna ; Langley, Joanne M ; Brousseau, Nicholas ; Brundin-Mather, Rebecca

Two new RSV immunization products exist for infants: a prenatal vaccine (RSVpreF) and a long-acting monoclonal antibody for infants (nirsevimab). While both showed promise in clinical trials, implementation has varied across jurisdictions. Before rollout in Canada, we conducted an anonymized, online survey with a nationally representative sample of 1,015 expectant and recent birth parents. The primary outcome was product acceptability (disagree, undecided, agree). Odds ratios (ORs) and 95% confidence intervals (CIs) identified factors associated with agreement or indecision versus disagreement. Approximately 49% (n = 499) were expecting; 51% (n = 516) had a baby in the past year. Overall, 72% (n = 727) agreed to receive a product: 61% (n = 624) for RSVpreF and 60% (n = 608) for nirsevimab. RSVpreF agreement was higher among older parents (e.g., OR = 3.64; 95% CI, 1.99-6.67 for age 25-34 versus 18-24 years), those with a university degree (OR = 3.65; 95% CI, 2.01-6.64 versus high school), higher income (OR = 2.31; 95% CI, 1.01-5.28 for ≥$150k versus <$40k), or receipt/intention for Tdap (OR = 3.76; 95% CI, 2.37-5.96 versus no receipt/intention) or influenza (OR = 2.04; 95% CI, 1.29-3.21) vaccines. Agreement was higher among parents of children without a high-risk medical condition compared to those with (OR = 2.32; 95% CI, 1.44-3.72). Similar trends were observed for nirsevimab, with lower agreement also noted among those who self-researched antibodies (OR = 0.51; 95% CI, 0.30-0.88 versus not). As most respondents rated product safety (76%), effectiveness (71%), and disease severity risk (70%) as important in decision-making, providing clear information on these, alongside communications targeted to subgroups with lower agreement, may optimize uptake as programs rollout.

31 Dec 2026·Expert Review of Vaccines

Cost-effectiveness and public health impact of RSV immunization for all infants in Japan: a mixed strategy with nirsevimab and RSVpreF

Article

Author: Arashiro, Takeshi ; Musci, Robert ; Ishiwada, Naruhiko ; Ghemmouri, Mehdi ; Yarnoff, Benjamin ; Wang, Xinyu ; Reygrobellet, Camille

BACKGROUND:

Respiratory syncytial virus (RSV) remains a leading cause of medically attended lower respiratory tract disease (MA-LRTD) among infants in Japan. With the approval of maternal immunization (MI) and nirsevimab, Japan is transitioning from high-risk-targeted prophylaxis toward broader RSV prevention. This study evaluated the public health and economic impact of alternative MI and nirsevimab strategies within the Japanese National Immunization Program (NIP).

RESEARCH DESIGNS AND METHODS:

A static decision-analytic cohort model estimated clinical and economic outcomes from birth through the first year of life (and the second RSV season for eligible high-risk infants). Strategies included an NIP-aligned scenario reflecting expected MI and nirsevimab, mixed nirsevimab-MI coverage scenarios, and nirsevimab-only. Outcomes included MA-LRTDs, hospitalizations, costs, quality-adjusted life-years (QALYs), and number needed to immunize (NNI) from payer and societal perspectives.

RESULTS:

Compared with the NIP-aligned scenario, shifting coverage toward greater nirsevimab use reduced MA-LRTDs by 9.6% to 28.1%. A nirsevimab-only strategy reduced MA-LRTDs by 34.3% and hospitalizations by 33.4%. Under base-case assumptions, strategies with greater nirsevimab use improved outcomes and reduced costs, with lower NNI as coverage increased.

CONCLUSIONS:

For the Japanese setting, greater nirsevimab use improves outcomes and reduces costs, with nirsevimab-only strategies providing the greatest overall benefit.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Mucosal immunization with an adenoviral vector expressing a prefusogenic F protein protects the upper and lower respiratory tracts of cotton rats against live respiratory syncytial virus challenge

Article

Author: Wang, Shen ; Wang, Qiyao ; Bao, Jianwei ; Lu, Shuangshuang ; Wu, Ke ; Xu, Long ; Mu, Ting ; Zhang, Ying ; Xie, Liang ; Klein, Michel ; Sun, Bing ; Ma, Tao

Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in infants, young children, and the elderly. Current licensed prefusogenic F-based RSV vaccines induce systemic immune responses through intramuscular injection. However, mucosal immunization will be required to elicit local sterilizing immunity to prevent virus replication in the nasopharynx and the lungs as well as virus shedding and transmission. Adenovirus vectors are a promising platform to develop RSV vaccines, but further evaluation of mucosal adenovirus-based prefusion F (preF) vaccines is still needed. In this study, we constructed a recombinant chimpanzee adenovirus serotype 68 vector expressing a second-generation disulfide-stabilized (DS2)trimeric preF protein (ChAd68-PreF). In mice, intranasal immunization with ChAd68-PreF induced dose-dependent increase in RSV-specific secretory IgA (sIgA) in the lower respiratory tract, demonstrating its capacity to elict mucosal immunity. Subsequently, in cotton rats, intratracheal instillation of ChAd68-PreF induced high cross-neutralizing antibody titers against RSV A and RSV B. After RSV A2 challenge, ChAd68-PreF vaccinated animals showed no detectable viral replication in the nose nor in the lungs. Moreover, ChAd68-PreF vaccination did not lead to enhanced respiratory disease (ERD) in cotton rats. These results demonstrate that mucosal delivery of ChAd68-PreF confers potent protective immunity against RSV with good safety profile, warranting further clinical development as a mucosa-targeting RSV vaccine for vulnerable populations.

404

News (Medical) associated with RSVpreF

04 Aug 2026

·firstwordpharma.com

Pfizer expands cost-cutting efforts with new $2.5B target

Pfizer is extending its cost-cutting drive again, this time with plans to unlock an additional $2.5 billion in savings between 2027 and 2029. That brings its total expected net savings from its various restructuring initiatives in recent years to $9.7 billion through 2029.The latest measures include $1 billion in further productivity savings from technology and simplification initiatives, as well as $1.5 billion from the next phase of its manufacturing optimisation programme, which will focus on network structure changes, enhancements to its product portfolio and more operational efficiencies."We have made meaningful progress on our productivity enhancement initiatives and remain on track to deliver most of the anticipated $7.2 billion in total net cost savings by the end of 2026," said Cecile Guegan, interim chief financial officer replacing Dave Denton, in prepared remarks during the company's second-quarter earnings call Tuesday.Eliquis, Padcev top estimatesThe announcement accompanied stronger-than-expected quarterly results. Overall revenues in the three months ended June were up 3% year-over-year to $15 billion, beating forecasts of $14.4 billion. Pfizer nevertheless reported a net loss of $248 million, versus net income of $2.9 billion in the corresponding year-ago quarter, due to $4.3 billion in non-cash asset impairments mostly tied to disappointing results from a Phase III lung cancer trial of sigvotatug vedotin.Regarding individual drug products, sales were led by the anticoagulant Eliquis, which climbed 21% to $2.4 billion, above analyst expectations of roughly $2 billion. Bladder cancer therapy Padcev, an antibody-drug conjugate Pfizer acquired through its $43-billion takeover of Seagen in 2023, also exceeded forecasts, with sales rising 23% to $667 million, topping consensus estimates of about $634 million.Other growth products included the Vyndaqel franchise (+9%, $1.8 billion), Nurtec ODT/Vydura (+18%, $421 million), Lorbrena (+41%, $354 million) and Abrysvo (+46%, $208 million).Lower COVID outlookHowever, COVID-19 products continued to weigh on results amid subdued demand. Sales of Pfizer's Comirnaty vaccine fell 32% to $261 million, while its Paxlovid treatment for COVID-19 infection plunged 95% to just $21 million. Pfizer lowered its full-year outlook for those products to a combined $4 billion, down from about $5 billion previously."Low COVID-19 incidence could continue to limit Paxlovid utilisation," Guegan said. "Our plan also assumes the majority of Comirnaty sales will occur toward year-end, consistent with the vaccination season."Despite the weaker COVID-19 product outlook, Pfizer did bump up the lower end of its 2026 revenue guidance to between $60.5 billion and $62.5 billion, from a previous range of $59.5 billion to $62.5 billion; it reaffirmed its adjusted earnings guidance of $2.80 to $3.00 per share. Management attributed the improved revenue outlook to a better-than-expected increase from its non-COVID portfolio of $1.5 billion.Pipeline cutsMeanwhile, Pfizer cleared some programmes from its pipeline. On the chopping block are MET-224o (PF-08656796), an oral, fully biased, ultra-long-acting GLP-1 receptor agonist in Phase I testing for chronic weight management. The company had acquired the compound through its hard-fought takeout of Metsera for $10 billion last year.It is also dropping development of another obesity candidate, PF-07976016, a GIP receptor antagonist that was in Phase II.Other discontinued programmes include PF-07985631, which was under development for nephropathy, and PF-07258669, an MC4R antagonist that Pfizer was working on to treat conditions like cachexia and anorexia-associated weight loss. Both of the programmes were in Phase I testing.

VaccinePhase 2Phase 1AcquisitionClinical Result

22 Jul 2026

·www.fiercepharma.com

FDA calls out Sanofi emails for giving 'misleading impression' of Beyfortus use in RSV

The FDA has called out Sanofi’s promotion of respiratory syncytial virus (RSV) antibody Beyfortus in a new untitled letter, taking issue with the company’s characterization of the med as a general RSV preventative. As the FDA explains in the letter (PDF), Beyfortus’ 2023 U.S. approval specifically clears the drug as a defense against RSV lower respiratory tract disease. Sanofi’s promotional emails (PDF) regarding Beyfortus, on the other hand, urge healthcare professionals to “help prevent RSV disease in infants,” creating what the FDA’s Office of Prescription Drug Promotion (OPDP) deems a “misleading impression” about the drug’s indication. Specifically, the Sanofi emails seem to point to Beyfortus' use as a general RSV preventative, “including both upper and lower respiratory tract disease, when this is not the case,” the FDA explained. In its promotional emails (PDF) flagged by the FDA, the company refers to Beyfortus as a monoclonal antibody to help prevent “RSV disease” numerous times. Although Sanofi does mention Beyfortus’ official indication to prevent RSV lower respiratory tract infection further down in the emails—and also notes the indication in full in its ‘indication’ section—the agency maintains that the “presentation of this information is not sufficient to correct the overall misleading impression created by these claims.” The letter asks that Sanofi take “immediate action” to address the concerns and submit a written response within 15 working days from the date of receipt. A Sanofi spokesperson acknowledged the untitled letter in an emailed statement to Fierce Pharma Marketing, noting that the company takes “this matter seriously" and is "reviewing the letter carefully.” “Sanofi maintains strict regulatory compliance policies for its promotional communications. We are committed to ensuring that all promotional materials for Beyfortus are accurate, balanced, and fully compliant with FDA regulations. We will respond to the agency within the required timeframe,” the spokesperson added. The new OPDP letter, released to the public on July 22 and dated July 15, comes as the company faces separate marketing backlash in the U.K. from the country's drug marketing watchdog, the PMCPA. On July 21, the PMCPA hit Sanofi with a public reprimand for “very serious breaches” of the Association of the British Pharmaceutical Industry (ABPI) code based on its Beyfortus claims across the pond. The case goes back to a 2024 article in which Sanofi’s former CEO Paul Hudson was quoted saying that the U.K.'s national RSV vaccine program should consider Beyfortus instead of Pfizer’s Abrysvo, which led Pfizer to contact the PMCPA over the article and two others, plus a press release. Sanofi could still face further sanctions over the matter in the U.K. and is to provide the PMCPA with a copy of a third-party audit report it has arranged for. The high level of regulatory scrutiny over the case stems from the PMCPA’s conclusion that the company’s claims could “undermine the public’s trust in vaccination campaigns” and spark decreasing vaccine rates and public health concerns. Last year, Sanofi’s global Beyfortus sales totaled 1.78 billion euros ($2.03 billion), representing 5.6% growth from 2024. The company co-developed the med with AstraZeneca and brought it to the U.S. market in July 2023. The duo shares the RSV-LRTI prevention market with Merck and its Enflonsia , while Pfizer’s Abrysvo can be used as a maternal vaccine in pregnant women to prevent RSV in children from birth.

Vaccine

09 Jul 2026

·www.pharmaceutical-technology.com

Moderna secures up to 24 million RSV vaccine dose contract with Europe

According to the EC, the procurement is an important step in reducing the burden on healthcare services. Credit: Billion Photos/Shutterstock.com. Moderna has agreed a contract with the European Commission (EC) that will see tens of millions of respiratory syncytial virus (RSV) vaccine doses accessible to member countries in time for the 2026-2027 winter season. Upon the request of six unnamed countries, the EC signed a joint procurement framework contract with Moderna to access up to 24 million doses of the mRNA-based mRESVIA, with no minimum order required. The contract will run for a period of up to four years. Moderna’s mRESVIA was approved in Europe for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older in August 2024. The vaccine has also been available to younger age groups who are at increased risk of RSV-induced disease. Earlier this year, a European Medicines Agency (EMA) committee recommended that the license be expanded to include all adults aged 18 years and older, meaning the jab’s use could significantly expand. This vaccine protects against diseases of the lungs, such as bronchitis and pneumonia, caused by RSV in adults. mRESVIA delivers genetic instructions to cells so they can synthesise an inert form of the virus. Once the system recognises this protein, it produces protective antibodies. RSV is a common respiratory virus that causes mild, cold-like symptoms. While most people usually recover in around a week without the need for medical treatment, RSV can cause severe illness and death in more vulnerable groups such as older adults. Over 156,000 adults are hospitalised in Europe each year due to the virus. According to the EC, the procurement is an important step in reducing the burden on healthcare services, especially during the winter season when RSV cases – and other infectious diseases – are at their highest. The European Centre for Disease Prevention and Control has maintained the importance of immunisation in vulnerable population groups. Wider access to a preventative vaccine also reduces antibiotic consumption, lowering the number of patients who are prescribed antibiotics unnecessarily or as a precaution. Combatting antimicrobial resistance is a key target of the EMA. Hadja Lahbib, European commissioner for equality, preparedness and crisis management, said: “With today’s joint procurement for an RSV vaccine, we are helping member states to enhance their preparedness against this serious virus before the upcoming winter season. This will protect the most vulnerable and reduce the pressure that respiratory infections place on our hospitals during the winter months. Being prepared today means saving lives when the next peak season arrives.” The EC’s procurement of mRESVIA contrasts with a more hesitant approach in the US, where there have been significant policy shifts to reduce reliance on mRNA-based products. The US Food and Drug Administration (FDA) widened mRESVIA’s use to all adults at increased risk of lower tract respiratory disease (LRTD) caused by RSV in June 2025. However, it has still not been recommended for all adults regardless of disease risk. Moderna’s main competitors in the RSV space are GSK’s Arexvy and Pfizer’s Abrysvo, which remain the top-selling RSV vaccines globally.

VaccineDrug ApprovalmRNAClinical Study

100 Deals associated with RSVpreF

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pneumonia due to respiratory syncytial virus	European Union	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Iceland	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Liechtenstein	Pfizer Europe MA EEIG	23 Aug 2023
Pneumonia due to respiratory syncytial virus	Norway	Pfizer Europe MA EEIG	23 Aug 2023
Respiratory Syncytial Virus Infections	United States	Pfizer Inc.	31 May 2023
Lower Respiratory Tract Infections	Canada	Pfizer Canada ULC	04 Jan 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Tract Infections	Phase 3	United States	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Japan	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Argentina	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Australia	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Brazil	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Canada	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Chile	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Denmark	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Finland	Pfizer Inc.	17 Jun 2020
Respiratory Tract Infections	Phase 3	Gambia	Pfizer Inc.	17 Jun 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06325657 (MORISOT, CTgov)	Phase 3	Respiratory Syncytial Virus Infections	681	RSVpreF (Maternal Participants: RSVpreF)	lxacsliwwu = xnhibdyhts clxckkbwak (vfyahksfqk, ioiakgakhh - dylsbjeoms) View more	-	02 Jul 2026
				placebo+RSVpreF (Maternal Participants: Placebo)	lxacsliwwu = edkrckzkrj clxckkbwak (vfyahksfqk, dopbqnmtft - gsygsvtapl) View more
NCT06593587 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	378	Placebo	xzscvnljfk = gjtmsbhudq hsowhjcueg (clrmqueqhy, olrgkjkgxi - cogfdxoyna) View more	-	09 Feb 2026
NCT06473519 (Amélie, CTgov)	Phase 3	Respiratory Syncytial Virus Infections	453	RSVpreF (RSVpreF (With Preservative, MDV))	tfhjhygklj(wlepxyymkg) = wacoujrwpx larywpmcgl (rhocjsnzkx, wodbctulzk - gknroihmaa) View more	-	25 Sep 2025
				RSVpreF (RSVpreF (Without Preservative, SDV))	tfhjhygklj(wlepxyymkg) = wmwwnlfqvo larywpmcgl (rhocjsnzkx, xhpmapoins - znesxsxcoi) View more
NCT05842967 (MONET, CTgov)	Phase 3	Respiratory Syncytial Virus Infections	885	SSA+RSVpreF (SSA: RSVpreF)	rojbgmncvl = tmcnxrqusn cuibqenumh (dxscrxpbhv, ovxwpimjiz - xdxsobboxy) View more	-	08 Aug 2025
				SSA (SSA: Placebo)	rojbgmncvl = sogspyslca cuibqenumh (dxscrxpbhv, aartupmzhm - nkcgombujn) View more
NCT04424316 (MATISSE, CTgov)	Phase 3	Respiratory Tract Infections	14,727	RSVpreF (Infant Participants: RSVpreF)	akcacsptai = mmemmiweke imyidltxux (teljfyyecn, onhrspfbno - etxawrzouj) View more	-	11 Feb 2025
				placebo+RSVpreF (Infant Participants: Placebo)	akcacsptai = woxtwefkda imyidltxux (teljfyyecn, tkneioxyia - llucifdfsd) View more
NCT05035212 (2021-003693-31, Pubmed \| Clin Infect Dis)	Phase 3	-	-	Bivalent RSV Prefusion F (RSVpreF) Vaccine (RSVpreF 120-µg)	xawxazymgo(vrbcaynghg) = cvbzbcyljq xkdaxhiham (kibpshjhra )	Positive	10 Feb 2025
				Bivalent RSV Prefusion F (RSVpreF) Vaccine (Placebo)	xawxazymgo(vrbcaynghg) = kkrlxkxvji xkdaxhiham (kibpshjhra )
NCT04424316 (MATISSE, Pubmed \| Obstet Gynecol)	Phase 3	Obstetric Labor, Premature	-	Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVpreF)	dljsjrmcks(fsbhdrwssr) = no clinically significant increase in adverse events of special interest, including preterm birth, low birth weight, or neonatal hospitalization, was observed among pregnant people in the overall analysis ufcorbmdye (ltzgbqhecy ) View more	Positive	01 Feb 2025
				Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (Placebo)
NCT05842967 (MONeT, PipelineReview) Manual	Phase 3	Respiratory Syncytial Virus Infections	203	ABRYSVO	ndkatdolnm(ajpijlohvl) = ABRYSVO was well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine. zehxegowdn (oumkqcanfg ) View more	Positive	12 Aug 2024
NCT04785612 (Phase 2a study, CTgov)	Phase 2	Respiratory Syncytial Virus Infections	70	RSVPreF (RSVPreF)	rdbpdvdqnk(bdsvgzpxtp) = pbkqsyuokw lrcjxphpfq (jesixrlrvi, gnjbwaewym - zypsrigrud) View more	-	07 Aug 2024
				Placebo (Placebo)	rdbpdvdqnk(bdsvgzpxtp) = umayhibqul lrcjxphpfq (jesixrlrvi, adsrtmxixs - squzktzctw) View more
NCT04424316 (MATISSE, Pubmed)	Phase 3	Respiratory Syncytial Virus Infections	-	RSVpreF vaccine	gmjsgkotrs(qopfichvnv) = xrormzdnmo cysetfkwhx (ryvoszyjge ) View more	Positive	08 Jun 2024
				bivalent RSVpreF maternal vaccination (Placebo)	gmjsgkotrs(qopfichvnv) = rdekybqipc cysetfkwhx (ryvoszyjge ) View more